A Study Evaluating the Safety of Cal-1 (LVsh5/C46) Drug Product in HIV-1 Infected Patient With High Risk Lymphoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- HIV -1 Infection
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 60 years
- Gender
- Both males and females
Description
not provided
not provided
Tracking Information
- NCT #
- NCT03593187
- Collaborators
- CSL Behring
- Investigators
- Study Chair: Marina CAVAZZANA, MD, PhD Assistance Publique - Hôpitaux de Paris Principal Investigator: Eric OKSENHENDLER, MD, PhD Assistance Publique - Hôpitaux de Paris
Get Well Soon